| ABBVIE INC. DL-,01 |
| USA |
| Gesundheit |
| US00287Y1091 / A1J84E |
| 4AB (Frankfurt) / ABBV (NYSE) |
| FRA:4AB, ETR:4AB, 4AB:GR, NYSE:ABBV |
| S&P500 |
| https://www.abbvie.com/ |
|
AbbVie Inc. is a global biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies for complex and serious diseases. AbbVie focuses on major therapeutic areas including immunology, oncology, neuroscience, eye ca..
>Volltext.. |
| 417186.66 Mio. EUR |
| 473294.63 Mio. EUR |
| 57196.16 Mio. EUR |
| 26577.12 Mio. EUR |
| 5568.07 Mio. EUR |
| 3.14 EUR |
| 62913.46 Mio. EUR |
| 5835.45 Mio. EUR |
| 17328.7 Mio. EUR |
| 0.16 |
| 13.86% |
| 73.66% |
| 5.88 EUR |
| 2.57% |
| 2.63% |
| 15.07.26 - 1.5115011€ 15.04.26 - 1.467559€ >weitere anzeigen... |
| - |
| ABBVIE |
| 07.10.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|